Literature DB >> 32128927

White and Gray Matter Abnormalities in Manifest Huntington's Disease: Cross-Sectional and Longitudinal Analysis.

Wafaa Sweidan1, Fen Bao2, Navid-Seraji Bozorgzad3, Edwin George2.   

Abstract

BACKGROUND AND
PURPOSE: Early white matter (WM) changes and cortical atrophy in Huntington's disease (HD) are often evident before disease onset and extend through the brain during manifest stages. The trajectory of these brain abnormalities in symptomatic stages remains relatively unexplored. The aim of this study is to investigate how the pattern of WM and gray matter (GM) alterations progress over time.
METHODS: We investigated alterations in brain WM, cortical thickness, and subcortical structures using diffusion and structural magnetic resonance imaging, in manifest HD patients (n = 13) compared to age-matched healthy controls (n = 11). Imaging and clinical data for the HD group were collected at follow-up (7 months) to explore possible longitudinal changes.
RESULTS: Cross-sectional analyses identified significant posterior cortical thinning (P < .05) and symmetric fractional anisotropy (FA) reduction (P < .01) in brain WM of HD group compared to HC. These changes were strongly correlated with impairment in motor symptoms and processing speed. Subcortical atrophy was significant in caudate, putamen, globus pallidus, and thalamus (P < .001). Regions of interest analysis revealed a significant reduction in FA of the corpus callosum (CC) (-2.19%, P < .05) upon follow-up, whereas no significant cortical thinning and subcortical atrophy was found.
CONCLUSIONS: This study showed broad GM and WM abnormalities in manifest HD patients. Reductions in FA and cortical thinning correlated significantly with the disturbances of motor and cognitive processing that describe HD. Follow-up assessment showed that the CC is compromised in the absence of detectable GM changes or motor decline, suggesting it plays an important role in disease progression.
© 2020 by the American Society of Neuroimaging.

Entities:  

Keywords:  Huntington's disease; clinical markers; cortical thinning; white matter

Mesh:

Year:  2020        PMID: 32128927      PMCID: PMC7489289          DOI: 10.1111/jon.12699

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  22 in total

1.  The B-matrix must be rotated when correcting for subject motion in DTI data.

Authors:  Alexander Leemans; Derek K Jones
Journal:  Magn Reson Med       Date:  2009-06       Impact factor: 4.668

2.  Longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging.

Authors:  Tara Madhyastha; Susan Mérillat; Sarah Hirsiger; Ladina Bezzola; Franziskus Liem; Thomas Grabowski; Lutz Jäncke
Journal:  Hum Brain Mapp       Date:  2014-04-03       Impact factor: 5.038

Review 3.  FreeSurfer.

Authors:  Bruce Fischl
Journal:  Neuroimage       Date:  2012-01-10       Impact factor: 6.556

4.  Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease.

Authors:  M Mühlau; A Weindl; A M Wohlschläger; C Gaser; M Städtler; M Valet; C Zimmer; J Kassubek; A Peinemann
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

5.  Estimation of the effective self-diffusion tensor from the NMR spin echo.

Authors:  P J Basser; J Mattiello; D LeBihan
Journal:  J Magn Reson B       Date:  1994-03

6.  Longitudinal change in white matter microstructure in Huntington's disease: The IMAGE-HD study.

Authors:  Govinda R Poudel; Julie C Stout; Juan F Domínguez D; Andrew Churchyard; Phyllis Chua; Gary F Egan; Nellie Georgiou-Karistianis
Journal:  Neurobiol Dis       Date:  2014-12-12       Impact factor: 5.996

7.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

8.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

9.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2013-05-09       Impact factor: 44.182

10.  Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data.

Authors:  Stephen M Smith; Mark Jenkinson; Heidi Johansen-Berg; Daniel Rueckert; Thomas E Nichols; Clare E Mackay; Kate E Watkins; Olga Ciccarelli; M Zaheer Cader; Paul M Matthews; Timothy E J Behrens
Journal:  Neuroimage       Date:  2006-04-19       Impact factor: 6.556

View more
  3 in total

1.  Investigating longitudinal changes to frontal cortico-striatal tracts in Huntington's disease: the IMAGE-HD study.

Authors:  Brendan Tan; Rosita Shishegar; Stuart Oldham; Alex Fornito; Govinda Poudel; Nellie Georgiou-Karistianis
Journal:  Brain Imaging Behav       Date:  2022-06-29       Impact factor: 3.978

Review 2.  Diffusion imaging in Huntington's disease: comprehensive review.

Authors:  Carlos Estevez-Fraga; Rachael Scahill; Geraint Rees; Sarah J Tabrizi; Sarah Gregory
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-10-08       Impact factor: 10.154

3.  Time will tell: Decision making in premanifest and manifest Huntington's disease.

Authors:  Beatrice Heim; Marina Peball; Carsten Saft; Sarah Maria von Hein; Philipp Ellmerer; Johanna Maria Piater; Klaus Seppi; Atbin Djamshidian
Journal:  Brain Behav       Date:  2020-09-26       Impact factor: 2.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.